CB-839 (telaglenastat), a highly selective and orally bioavailable GLS inhibitor, has shown promising tolerability in early-phase clinical trials across hematologic malignancies including AML, with mostly low-grade adverse events reported and an acceptable safety profile even in combination regimens [81]. This evidence concerns the gene GLS and acute myeloid leukemia.